SS Innovations Int'l Performs 4,000 Robotic Surgeries

By Philip Seaworth • Tuesday, May 27 15:21 • Permanent Link

SS Innovations International, Inc. (NASDAQ: SSII) has achieved a significant milestone by successfully performing over 4,000 robotic surgeries using the SSI Mantra Surgical Robotic System. This achievement encompasses more than one hundred types of surgeries, including approximately 215 cardiac surgical procedures, with six of them being conducted via telesurgery in India.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, highlighted the system's world-class quality, differentiated features, ease of use, and its increasing acceptance among leading physicians in India and other markets. The SSI Mantra systems are currently approved for market in seven countries, with plans to enter the United States and European Union markets. The company aims for a European Union CE mark decision in late 2025 and a U.S. Food and Drug Administration decision in the first half of 2026.

The SSI Mantra has been utilized for various surgery types, including general surgery, gastrointestinal, urology, thoracic, gynecology, head and neck, cardiac, and breast and plastic surgeries.

The SSI Mantra is currently approved for market in India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine.

SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies with the vision of making the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes the proprietary SSI Mantra Surgical Robotic System and the comprehensive suite of SSI Mudra Surgical Instruments, supporting a variety of surgical procedures, including robotic cardiac surgery. SS Innovations is an American company headquartered in India and aims to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Following these announcements, the company's shares moved -22.56%, and are now trading at a price of $6.83. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.